HutchMed's Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
CompanyDrug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
CompanyDeals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
CompanyDrug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Sino Biopharmaceutical's TDI01 Enrolls First IPF Patient in World's First ROCK2 Inhibitor Phase III Trial
CompanyDrug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
CompanyDrug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Hansoh Pharma Licenses Hengrui's SHR6508 for RMB 220 Million to Expand Renal Portfolio
CompanyDeals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
CompanyDeals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
CompanyDeals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
CompanyDrug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
CompanyDrug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories